The American NHLBI gives credit to the Institute of Cardiology for its significant achievements in leading the ISCHEMIA trial in Poland

by Aleksandra Bąkała

It has been two years since the Polish launch of a large scale research project set to determine the role of early invasive diagnostics and coronary revascularization in patients with stable coronary artery disease and significant myocardial ischemia on stress testing.

The ISCHEMIA Trial is one or the largest multinational, randomized trial sponsored by the American National Heart, Lung, and Blood Institute (NHLBI). The trial’s results are to shape guidelines on stable coronary artery disease for many years to come.


The Institute of Cardiology in Warsaw leads and coordinates the work on the trial in Poland. It is worth mentioning that Poland as a country as well as the Institute as a site are among the world’s most active ISCHEMIA countries and sites. This top ranking position of the Institute would not be possible without availability of state-of-the-art, high-quality, high-tech noninvasive diagnostic technology and expertise.

The success of the Institute in leading the trial in Poland has been appreciated by the US NHLBI and the study chair in  correspondence cited below.

tl_file2/IKAR/images/breakLine.png
***
The National Heart, Lung, and Blood Institute of the United States National Institutes of Health, as the sponsor the ISCHEMIA trial, is very honored to partner with the Warsaw Institute of Cardiology and many other prestigious medical institutions in Poland, on the ISCHEMIA trial. We believe this trial, one of the largest international trials sponsored by the NHLBI, will be a landmark trial that will influence the practice of cardiovascular medicine for many years after it is completed. We are very grateful for the contributions of the Polish investigators so far. Poland has been one of the highest enrolling European countries thanks to several Polish sites, and we hope that this wonderful contribution will continue and expand as more Polish sites increase their involvement.
 
Yves D Rosenberg, M.D., M.P.H.
ISCHEMIA Project Officer
Chief, Atherothrombosis and Coronary Artery Disease Branch
Division of Cardiovascular Sciences
National Heart, Lung and Blood Institute

tl_file2/IKAR/images/breakLine.png
***
Dear Colleagues,
On behalf of the ISCHEMIA Trial Leadership Team, please accept our congratulations on your excellent work randomizing patients in Poland.  We are very grateful for your efforts and dedication to this important study.
Special thanks to the Institute of Cardiology for randomizing over 70 patients!
 
Dr. Judith Hochman
ISCHEMIA Study Chair

tl_file2/IKAR/images/breakLine.png

Go back